---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-014937"
form_type: "8-K"
ticker: "BIAF"
cik: "0001712762"
company_name: "bioAffinity Technologies, Inc."
filed_at: "2023-05-01T23:59:59+00:00"
generated_at: "2026-06-16T05:09:44.186002+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioAffinity appoints Michael Dougherty as CFO; former CFO Edwards resigns

## Summary
- Michael Edwards resigned as CFO effective May 1; will serve as consultant for transition.
- Michael Dougherty appointed CFO; previously CFO of Alexa Business Domains at Amazon.
- Dougherty receives $250K base salary, $30K cash signing bonus, plus $100K restricted stock grant.
- Dougherty brings 20+ years finance experience; will support commercial rollout of CyPath® Lung.
- Company is a biotech focused on noninvasive early-stage cancer detection.

## SEC filing metadata
- accession: 0001493152-23-014937
- form_type: 8-K
- ticker: BIAF
- cik: 0001712762
- company_name: bioAffinity Technologies, Inc.
- filed_at: 2023-05-01T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1712762/000149315223014937/0001493152-23-014937-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1712762/000149315223014937/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-014937
- JSON: https://secwatch.observer/filing/0001493152-23-014937.json
- Plain text: https://secwatch.observer/filing/0001493152-23-014937.txt

## Key facts
- Executive change
  Michael Dougherty was appointed as Vice President and Chief Financial Officer at bioAffinity Technologies, Inc..
  - Action: appointed
  - Role: Vice President and Chief Financial Officer
  source text: Effective May 1, 2023, the Company appointed Michael Dougherty (age 44) to serve as the Company’s new Vice President and Chief Financial Officer (principal financial officer and principal accounting officer).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315223014937/0001493152-23-014937-index.htm
- Executive change
  Michael Edwards resigned as Chief Financial Officer at bioAffinity Technologies, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective May 1, 2023, Michael Edwards, the Company’s Chief Financial Officer (principal financial officer and principal accounting officer), resigned.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1712762/000149315223014937/0001493152-23-014937-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.